Skip to content
Subscribe Follow on LinkedIn

Latest

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

✨ Onyx Summary Belite Bio (NASDAQ: BLTE) said the UK MHRA will accept a Conditional Marketing Authorization application for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results, with final topline data expected in Q4 2025 for subsequent full MAA submission. The pivotal DRAGON trial enrolled 104 adolescent patients

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Participate in Upcoming November Conferences

✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) announced its senior leadership will participate in the Truist Securities BioPharma Symposium on November 6, 2025, and the UBS Global Healthcare Conference on November 11, 2025, where it will host a fireside chat. The company continues to engage the investment community as it

Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting

Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting

✨ Onyx Summary Saama launched its Tables, Listings, and Figures (TLF) Analyzer, an AI-driven solution that automates interpretation and summarization of complex clinical data to accelerate clinical study report (CSR) authoring. Integrating multimodal GenAI capable of converting graphical outputs—such as Kaplan–Meier and forest plots—into context-rich text, the tool

Seer to Participate in Upcoming November Investor Conferences

Seer to Participate in Upcoming November Investor Conferences

✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced its participation in upcoming investor events, including one-on-one meetings at the UBS Global Healthcare Conference on November 12 and a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20. Live and archived webcasts of the

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) announced positive interim results from the Phase 2 portion of its registrational KYSA-6 trial showing that a single dose of KYV-101, a CD19 CAR T-cell therapy, achieved rapid, durable, and clinically meaningful improvements in all treated patients with generalized myasthenia gravis. The therapy demonstrated

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

✨ Onyx Summary Belite Bio (Nasdaq: BLTE) announced that its executive management team will present a corporate update at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025, at 10:30 a.m. ET. SAN DIEGO, Oct. 29, 2025 – Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

✨ Onyx Summary Legend Biotech (NASDAQ: LEGN) announced it will host a conference call on November 12, 2025, at 8:00 a.m. ET to discuss its third-quarter financial results and business performance. The company, co-developer of CARVYKTI® for multiple myeloma, continues to expand its leadership in cell therapy and build

Verily Accelerates Precision Health AI With NVIDIA

Verily Accelerates Precision Health AI With NVIDIA

✨ Onyx Summary Verily announced a collaboration with NVIDIA to integrate NVIDIA’s AI technology stack—including NeMo, Parabricks, and CUDA-X—into its Pre platform, significantly accelerating genomic and AI model analyses across healthcare research environments such as the NIH’s All of Us Researcher Workbench. The partnership enhances Verily’s

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

✨ Onyx Summary Geron Corporation (Nasdaq: GERN) announced it will release its third-quarter 2025 financial results and business highlights before market open on November 5, 2025, followed by a conference call and webcast at 8:00 a.m. ET. The live and archived webcast will be accessible on Geron’s investor

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) entered into a definitive agreement to be acquired by Novartis AG for $72.00 per share in cash, valuing Avidity at approximately $12 billion, following the planned spin-off of its early-stage precision cardiology programs into a new public company, SpinCo. The transaction, unanimously approved

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

✨ Onyx Summary Guardant Health (Nasdaq: GH) announced new data to be presented at the 2025 American College of Gastroenterology Annual Meeting demonstrating that its FDA-approved Shield blood test achieved over 90% adherence for colorectal cancer screening, significantly higher than traditional methods. The company also shared survey findings showing patient preference

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) reported positive Phase 1 results from an investigator-initiated trial of KYV-101, its CD19 CAR T-cell therapy, in treatment-refractory rheumatoid arthritis, showing strong CAR T-cell expansion, full B-cell depletion, and meaningful clinical responses with no high-grade adverse events. Presented by Charité – University of Berlin at